OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (166)	8/27/2002 10:19:35 AM
From: Vector1	Read Replies (1) of 447

Thanks Miljenko. I generally agree with your conclusion: <<Speculative translation suggest that OSIP two PIII front line program have small chance to be better than Iressa data. Third PIII trial, monotherapy for progressive lung cancer, may generate positive data (like Iressa), but overall dug utility will be far from expected.>> However, I bought OSIP because: I believe the PIII trial for refactory lung cancer for Tarceva is well designed and if successful will give Tarceva a very high chance of approval. In addition I think that Tarceva has a strong chance of positive results in combo with Gemzar in Pancreatic Cancer. Gemzar is limited and will generate $800m in sales. I do not think IRESSA will get approval based on existing data leaving Tarceva potentially as the first approved product. OSIP has $500m in cash/ V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next